Plain-English translation of NCT05136326 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether combining two oral medications— and —with radiation therapy can improve treatment outcomes for people with locally advanced rectal cancer. The trial focuses on patients whose tumors have specific genetic characteristics (MGMT silencing) that may make them respond better to this combination. About 21 patients will receive this combined treatment before surgery to see if it helps shrink their tumors more effectively than standard treatment alone.
Standard treatment for advanced rectal cancer works well for many patients, but doctors want to find better options, especially for patients who may not be candidates for the most intensive therapy approaches. By targeting tumors with specific genetic features, this medication combination may offer a more personalized approach that improves outcomes without unnecessarily intense treatment.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive radiation therapy 5 days a week for about 5 weeks, along with taking two oral medications twice daily during those same 5 weeks. Before starting treatment, you'll have imaging tests and blood work to confirm you're eligible. After completing the combined treatment, you'll have surgery to remove the cancer. During and after treatment, you'll have regular clinic visits to monitor your health and watch for side effects.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
Italy